RELEASE: Sirolimus-Coated Balloon in BTK Treatment Makes a Bold Presence at VEITH 2022

(Information sent by the signatory company).

RELEASE: Sirolimus-Coated Balloon in BTK Treatment Makes a Bold Presence at VEITH 2022

(Information sent by the signatory company)

-Sirolimus-coated balloon in the treatment of BTK makes a bold presence at VEITH 2022 - Illuminate New York's Times Square, NASDAQ

TAMPA, Fla., Dec. 5, 2022 /PRNewswire/ -- VEITH 2022 saw a surge of supporting clinical data for the Sirolimus Coated Balloon in the treatment of below-knee (BTK) disease. Concept Medical Inc. hosted a symposium entitled "Sirolimus-Coated Balloon in the Treatment of PAD: Choice of the Future", which explored the utility of Sirolimus-Coated Balloon treatment in PAD. The session was chaired by Prof. Sahil Parikh, co-moderated by Prof. Edward Choke and Prof. Aloke Finn, with interesting presentations by Prof. Ulf Teichgräber and Prof. Francesco Liistro.

One of the highlights of the session was the follow-up data on the clinical results of the XTOSI trial. XTOSI (Xtreme Touch Sirolimus coated PTA balloon) is a single-arm trial of the sirolimus-coated balloon (MagicTouch PTA) investigating the clinical use and safety of the device in the treatment of infrainguinal peripheral artery disease (PAD). This prospective, premarket, non-randomized, single-arm study, led by Professor Edward Choke, Principal Investigator, enrolled 50 patients to study the Magic Touch PTA (Concept Medical Inc.) sirolimus-coated balloon at Hospital Sengkang General, Singapore. This is the world's first trial of the sirolimus-coated balloon for BTK disease and has the longest follow-up data. Although the primary endpoints already suggested promising patency and safety at 6 months, the data presented at VEITH 2022 shed more light on the long-term efficacy and safety of the Sirolimus-Coated Balloon.

Prof. Edward Choke, further presented updates on the FUTURE SFA and FUTURE BTK RCTs, a family of randomized trials enrolling 279 and 219 patients, respectively, against a standard uncoated balloon in a 2:1 ratio and which they are ongoing in Singapore, Taiwan and Thailand. FUTURE BTK has already completed 25% of its enrollment goal, as confirmed by the principal investigators of all the centers involved.

The Sirolimus Coated Balloon for PAD continues its march, knocking on the doors of the US and lighting up New York's iconic Times Square with a dazzling display of XTOSI study results and FUTURE BTK recruitment status.

Watch the full session to learn more about the exciting clinical data:


View original content: